Quanterix Corporation (QTRX) Quick Ratio
- Quick ratio · latest quarter: Value 2.30×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.30× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $115.87M ÷ $50.37M ≈ 2.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 115.87M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 50.37M USD | Liabilities, Current |
| Cash and equivalents | 44.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 49.36M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 22.34M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 47.60M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $115.87M | $50.37M | $44.17M | $49.36M | $22.34M | $47.60M | 2.30× |
| 2026-03-31 | $126.04M | $49.91M | $36.18M | $63.08M | $26.78M | $50.96M | 2.53× |
| 2025-12-31 | $148.20M | $74.76M | $29.84M | $88.39M | $29.97M | $54.76M | 1.98× |
| 2025-09-30 | $167.84M | $77.35M | $38.30M | $96.51M | $33.03M | $54.96M | 2.17× |
| 2025-06-30 | $284.72M | $48.20M | $132.90M | $128.28M | $23.55M | $30.14M | 5.91× |
| 2025-03-31 | $295.13M | $40.40M | $76.51M | $190.37M | $28.26M | $31.03M | 7.31× |
| 2024-12-31 | $88.85M | $42.01M | $56.71M | $0.00 | $32.14M | $32.77M | 2.12× |
| 2024-09-30 | $324.61M | $36.45M | $29.34M | $264.18M | $31.09M | $32.97M | 8.90× |
| 2024-06-30 | $328.64M | $37.54M | $47.00M | $249.85M | $31.78M | $28.36M | 8.75× |
| 2024-03-31 | $331.20M | $32.24M | $45.28M | $256.64M | $29.28M | $26.02M | 10.27× |
| 2023-12-31 | $206.73M | $38.46M | $174.42M | $6.89M | $25.41M | $22.36M | 5.38× |
| 2023-09-30 | $351.79M | $35.15M | $201.26M | $126.45M | $24.08M | $19.95M | 10.01× |
| 2023-06-30 | (m) | $31.95M | $329.52M | (m) | $24.42M | $18.16M | (m) |
| 2023-03-31 | (m) | $26.94M | $329.35M | (m) | $22.55M | $17.07M | (m) |
| 2022-12-31 | (m) | $30.96M | $338.74M | (m) | $19.02M | $16.79M | (m) |
| 2022-09-30 | (m) | $28.57M | $343.74M | (m) | $18.33M | $18.24M | (m) |
| 2022-06-30 | (m) | $36.67M | $361.29M | (m) | $19.68M | $21.98M | (m) |
| 2022-03-31 | (m) | $31.77M | $374.32M | (m) | $22.62M | $22.67M | (m) |
| 2021-12-31 | (m) | $36.98M | $396.46M | (m) | $23.79M | $22.19M | (m) |
| 2021-09-30 | (m) | $31.19M | $410.75M | (m) | $18.43M | $22.79M | (m) |
| 2021-06-30 | (m) | $37.67M | $430.78M | (m) | $15.43M | $21.23M | (m) |
| 2021-03-31 | (m) | $36.49M | $442.67M | (m) | $14.94M | $17.04M | (m) |
| 2020-12-31 | (m) | $39.80M | $181.58M | (m) | $17.18M | $14.86M | (m) |
| 2020-09-30 | (m) | $28.09M | $173.16M | (m) | $26.26M | $13.27M | (m) |
| 2020-06-30 | (m) | $18.90M | $88.81M | (m) | $9.53M | $13.79M | (m) |
| 2020-03-31 | (m) | $18.01M | $96.36M | (m) | $12.06M | $11.39M | (m) |
| 2019-12-31 | (m) | $19.83M | $109.16M | (m) | $10.91M | $10.46M | (m) |
| 2019-09-30 | (m) | $18.22M | $113.33M | (m) | $11.91M | $11.16M | (m) |
| 2019-06-30 | (m) | $17.02M | $72.03M | (m) | $9.13M | $8.85M | (m) |
| 2019-03-31 | (m) | $16.60M | $33.97M | (m) | $7.30M | $7.74M | (m) |
| 2019-01-01 | (m) | (m) | (m) | (m) | $6.84M | (m) | (m) |
| 2018-12-31 | (m) | $18.13M | $44.43M | (m) | $6.79M | $5.95M | (m) |
| 2018-09-30 | (m) | $15.24M | $51.42M | (m) | $4.65M | $5.38M | (m) |
| 2018-06-30 | (m) | $23.36M | $60.47M | (m) | $3.59M | $5.49M | (m) |
| 2018-03-31 | (m) | $22.79M | $65.23M | (m) | $4.66M | $5.33M | (m) |
| 2017-12-31 | (m) | $19.71M | $79.68M | (m) | $5.60M | $3.57M | (m) |
| 2017-03-31 | (m) | (m) | $24.56M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $29.67M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |